Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer
Authors: Patricia A. Ganz
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. February 17, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02671 Journal of Clinical Oncology - published online before print February 24, 2023 PMID: 36827741 Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer Patricia A. Ganz , MD1,2xPatricia A. GanzSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2UCLA‐Jonsson Comprehensive Cancer Center, Center for Cancer Prevention and Control Research, University of California, Los Angeles, CA https://doi.org/10.1200/JCO.22.02671 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 1999, Harvey et al1 demonstrated that the immunohistochemistry method for assessing estrogen receptor in breast cancer pathological specimens was superior to the ligand-binding assay in predicting survival outcomes after adjuvant endocrine therapy. In addition, a new scoring system used with the immunohistochemistry method was demonstrated to be reliable and valid, detecting low levels of estrogen receptor expression in tumors that had not been appreciated with the ligand-binding assay.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Patricia A. GanzLeadership: Intrinsic LifeSciences (I)Stock and Other Ownership Interests: Xenon Pharma (I), Intrinsic LifeSciences (I), Silarus Therapeutics (I), Teva, Novartis, Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Abbott LaboratoriesConsulting or Advisory Role: InformedDNA, Vifor Pharma (I), Ambys Medicines (I), Global Blood Therapeutics (I), GlaxoSmithKline (I), Ionis Pharmaceuticals (I), Akebia Therapeutics (I), Protagonist Therapeutics (I), Regeneron (I), Sierra Oncology (I), Rockwell Medical Technologies Inc (I), Astellas Pharma (I), Gossamer Bio (I), American Regent (I), Disc Medicine (I), Blue Note Therapeutics, GrailResearch Funding: Blue Note Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: related to iron metabolism and the anemia of chronic disease (I), Up-to-Date royalties for section editor on survivorshipTravel, Accommodations, Expenses: Intrinsic LifeSciences (I)No other potential conflicts of interest were reported. Companion Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer